Neurologic Recovery in MPS I and MPS II Mice by AAV9-Mediated Gene Transfer to the CNS After the Development of Cognitive Dysfunction
Human Gene Therapy · 2023
DOI: 10.1089/hum.2022.162 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Gene Therapy, 2023. Verfasst von Kelly M Podetz-Pedersen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, Cell Biology and Development, Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Mucopolysaccharidosis II, Mucopolysaccharidosis I, Iduronate Sulfatase, Nervous System Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
The mucopolysaccharidoses (MPS) are a group of recessively inherited conditions caused by deficiency of lysosomal enzymes essential to the catabolism of glycosaminoglycans (GAG). MPS I is caused by deficiency of the lysosomal enzyme alpha-L-iduronidase (IDUA), while MPS II is caused by a lack of iduronate-2-sulfatase (IDS). Lack of these enzymes leads to early mortality and morbidity, often including neurological deficits. Enzyme replacement therapy has markedly improved the quality of life for MPS I and MPS II affected individuals but is not effective in addressing neurologic manifestations. For MPS I, hematopoietic stem cell transplant has shown effectiveness in mitigating the progression of neurologic disease when carried out in early in life, but neurologic function is not restored in patients transplanted later in life. For both MPS I and II, gene therapy has been shown to prevent neurologic deficits in affected mice when administered early, but the effectiveness of treatment after the onset of neurologic disease manifestations has not been characterized. To test if neurocognitive function can be recovered in older animals, human IDUA or IDS-encoding AAV9 vector was administered by intracerebroventricular injection into MPS I and MPS II mice, respectively, after the development of neurologic deficit. Vector sequences were distributed throughout the brains of treated animals, associated with high levels of enzyme activity and normalized GAG storage. Two months after vector infusion, treated mice exhibited spatial navigation and learning skills that were normalized, that is, indistinguishable from those of normal unaffected mice, and significantly improved compared to untreated, affected animals. We conclude that cognitive function was restored by AAV9-mediated, central nervous system (CNS)-directed gene transfer in the murine models of MPS I and MPS II, suggesting that gene transfer may result in neurodevelopment improvements in severe MPS I and MPS II when carried out after the onset of cognitive decline.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Genetics, Cell Biology and Development, Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota, USA.
- REGENXBIO, Inc., Rockville, Maryland, USA.
ORCID-Profile: Miles C Smith, Lalitha R Belur
Förderung
- NINDS NIH HHS
- NIDDK NIH HHS
Zitieren
APA
Podetz-Pedersen, K. M., Laoharawee, K., Singh, S., Nguyen, T. T., Smith, M. C., Temme, A., Kozarsky, K., McIvor, R. S., & Belur, L. R. (2023). Neurologic Recovery in MPS I and MPS II Mice by AAV9-Mediated Gene Transfer to the CNS After the Development of Cognitive Dysfunction. Human Gene Therapy. https://doi.org/10.1089/hum.2022.162
Vancouver
Podetz-Pedersen KM, Laoharawee K, Singh S, Nguyen TT, Smith MC, Temme A, et al. Neurologic Recovery in MPS I and MPS II Mice by AAV9-Mediated Gene Transfer to the CNS After the Development of Cognitive Dysfunction. Human Gene Therapy. 2023. doi:10.1089/hum.2022.162
BibTeX
@article{PodetzPedersen2023,
author = {Podetz-Pedersen, Kelly M and Laoharawee, Kanut and Singh, Sajya and Nguyen, Tam T and Smith, Miles C and Temme, Alexa and Kozarsky, Karen and McIvor, R Scott and Belur, Lalitha R},
title = {Neurologic Recovery in MPS I and MPS II Mice by AAV9-Mediated Gene Transfer to the CNS After the Development of Cognitive Dysfunction},
journal = {Human Gene Therapy},
year = {2023},
doi = {10.1089/hum.2022.162}
}
EUVIMED